Equine Encephalitis - Pipeline Review, H2 2016 - Product Image

Equine Encephalitis - Pipeline Review, H2 2016

  • ID: 3946490
  • Report
  • 51 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Akshaya Bio Inc.
  • Altravax, Inc.
  • EpiVax, Inc.
  • MORE
Equine Encephalitis - Pipeline Review, H2 2016

Summary

Our latest Pharmaceutical and Healthcare disease pipeline guide Equine Encephalitis - Pipeline Review, H2 2016, provides an overview of the Equine Encephalitis (Central Nervous System) pipeline landscape.

Equine encephalitis (EE) is mosquito transmitted disease that can cause severe inflammation of the brain (encephalitis) in humans. Symptoms include the sudden onset of fever, chills, body and joint aches. Infection can develop into severe encephalitis, resulting in headache, disorientation, tremors, seizures and paralysis. Permanent brain damage, coma and death may also occur in some cases. Approximately a third of patients who develop EE die, and many of those who survive have mild to severe brain damage.

Report Highlights

Our Pharmaceutical and Healthcare latest pipeline guide Equine Encephalitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Equine Encephalitis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Equine Encephalitis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Equine Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 8 and 3 respectively for Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 2 and 1 molecules, respectively for Equine Encephalitis.

Equine Encephalitis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Equine Encephalitis (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Equine Encephalitis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Equine Encephalitis (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Equine Encephalitis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Equine Encephalitis (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Equine Encephalitis (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Equine Encephalitis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Akshaya Bio Inc.
  • Altravax, Inc.
  • EpiVax, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Equine Encephalitis Overview

Therapeutics Development

Pipeline Products for Equine Encephalitis - Overview

Pipeline Products for Equine Encephalitis - Comparative Analysis

Equine Encephalitis - Therapeutics under Development by Companies

Equine Encephalitis - Therapeutics under Investigation by Universities/Institutes

Equine Encephalitis - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Equine Encephalitis - Products under Development by Companies

Equine Encephalitis - Products under Investigation by Universities/Institutes

Equine Encephalitis - Companies Involved in Therapeutics Development

Akshaya Bio Inc.

Altravax, Inc.

EpiVax, Inc.

Integrated BioTherapeutics, Inc.

Karyopharm Therapeutics, Inc.

Profectus BioSciences, Inc.

Equine Encephalitis - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

DEF-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

equine encephalitis vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

equine encephalitis vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

equine encephalitis vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

imatinib mesylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies for Equine Encephalitis and Chikungunya - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody for Venezuelan Equine Encephalitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nilotinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TSI-GSD-104 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Western Equine Encephalitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

venezuelan equine encephalitis vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Venezuelan equine encephalitis vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

venezuelan equine encephalitis vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

verdinexor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Westrern Equine Encephalitis Virus Vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Equine Encephalitis - Dormant Projects

Equine Encephalitis - Product Development Milestones

Featured News & Press Releases

Dec 09, 2015: Profectus BioSciences Receives $4.6 Million DOD Grant to Develop Vaccine for Western, Eastern, and Venezuelan Equine Encephalitis Viruses

Dec 09, 2015: Profectus BioSciences Receives $4.6 Million DOD Grant to Develop Vaccine for Western, Eastern, and Venezuelan Equine Encephalitis Viruses

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Equine Encephalitis, H2 2016

Number of Products under Development for Equine Encephalitis - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Equine Encephalitis - Pipeline by Akshaya Bio Inc., H2 2016

Equine Encephalitis - Pipeline by Altravax, Inc., H2 2016

Equine Encephalitis - Pipeline by EpiVax, Inc., H2 2016

Equine Encephalitis - Pipeline by Integrated BioTherapeutics, Inc., H2 2016

Equine Encephalitis - Pipeline by Karyopharm Therapeutics, Inc., H2 2016

Equine Encephalitis - Pipeline by Profectus BioSciences, Inc., H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Equine Encephalitis - Dormant Projects, H2 2016

List of Figures

Number of Products under Development for Equine Encephalitis, H2 2016

Number of Products under Development for Equine Encephalitis - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Targets, H2 2016

Number of Products by Stage and Targets, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Akshaya Bio Inc.
Altravax, Inc.
EpiVax, Inc.
Integrated BioTherapeutics, Inc.
Karyopharm Therapeutics, Inc.
Profectus BioSciences, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll